Dr. Edginton’s research focuses on improving the confidence of physiologically-based pharmacokinetic (PBPK) model outcomes through understanding model inputs and developing modeling workflows.
Profiles
Filter by:
Dr. Abdullah Hamadeh is a Research Associate at the School of Pharmacy, University of Waterloo. He holds a Ph.D. in control systems engineering from the University of Cambridge and has conducted postdoctoral research in systems and synthetic biology at MIT.
Dr. Hamadeh specializes in developing optimization algorithms for complex systems, with a primary focus on applications in pharmacokinetic modeling, systems pharmacology, and epidemiology. His current research initiatives involve the development of learning algorithms that fuse experimental data and pharmacokinetic models to derive mechanistic insights that inform topical drug development and chemical risk assessment. Dr. Hamadeh is also a software developer and contributor to the Open Systems Pharmacology modeling platform.
Sam is a PhD student and a graduate from the UW School of Pharmacy PharmD Program (2019). Post-graduation, Sam completed his Accredited Canadian Pharmacy Residency (ACPR) at The Ottawa Hospital. His research focuses on developing and applying Physiologically-Based Pharmacokinetic models (PBPK) for clinical management of critically ill patients receiving continuous renal replacement therapy.
Sam is a PhD student being co-supervised by Dr. Edginton and Dr. Wong. She is currently studying the pharmacoeconomics of hemophilia A gene therapy, focusing on generating high-quality data from real-world sources to allow for more accurate cost-effectiveness modeling.
She obtained a BMath in Honours Mathematical Studies with minors in Applied Mathematics and Biology. During this time, she was awarded an NSERC Undergraduate Student Research Award for a computational-based project in the Brian Ingalls Lab. She transferred from the MSc program to the direct to PhD.
Dr. Chelle has a background in Health Engineering and has been working at the University of Waterloo, School of Pharmacy, since 2017.
His work at UW focuses on Population PK modeling with research interests including data analysis, Bayesian forecasting and development of R code based tools.
He is also involved the several projects including WAPPS-Hemo (www.wapps-hemo.org) which aims at empowering hemophilia treatment by facilitating individualized dosing; the development of an R toolbox for the Open System Pharmacology Suite and the development of a dosing tool for the treatment of neonates having patent ductus arteriosus.
Ruby is the Research Administrative Assistant for Dr. Andrea Edginton.
Dagmar obtained her PhD degree in Statistics from the Statistics and Actuarial Science Department at UW after developing methodology for the analysis of longitudinal survey data. She has provided statistical consultation on a variety of PK/PD projects and delivered courses on advanced statistics for the application of pharmacokinetic NLME models. Dagmar's current role is population PK modeling in the WAPPS-Hemo project.
Dr. Min-Soo Kim is interested in applying pharmacokinetic models toward optimal drug therapy. He completed his PharmD program in 2016 at the College of Pharmacy, Korea University, and his Ph.D. in Pharmaceutical Science in 2022 at the College of Pharmacy, Seoul National University. His doctoral work developed physiologically based pharmacokinetic models for the prediction of the pharmacological effect of fexuprazan and the extent of atorvastatin-fimasartan interaction in humans. As a postdoctoral fellow, he is learning population pharmacokinetic modeling in this group, and developing pharmacokinetic models to propose optimal dosing regimens for new drug candidates and optimize a dosing regimen of a marketed drug in sub-populations.
Shirley holds a Bachelor of Science in Biochemistry and a Master of Science in Pharmacy, earned at the University of Waterloo. Her academic journey reflects a deep commitment to advancing pharmaceutical sciences, evident during her master's research in Alzheimer's drug discovery. There, she developed novel molecules targeting beta-amyloid aggregation, earning recognition with the Memorial poster award at the 2023 Canadian Society for Pharmaceutical Sciences conference. In her more than five years in small pharma, she honed her expertise in developing bioanalytical methods for assessing novel transdermal drug delivery technologies, contributing significantly to the pre-clinical studies. Now, in her Ph.D. pursuit, Shirley's passion for pharmacometrics drives her work on physiologically-based pharmacokinetic models, with a focus on advancing neonatal drug exposure assessment during lactation. This work aims to provide a vital means of assessing infant risk when considering the continuation of medical treatments during pregnancy and breastfeeding.